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Introduction
The major function of the skin is to prevent loss of water from the 
body by formation of a permeability barrier. The barrier resides 
in the stratum corneum (SC) and is dependent on an extensive 
array of stacked multilamellar membranes that are attached to 
and intercalate between protein-rich corneocytes.1-3 The SC mem-
branes have a distinctive lipid composition consisting of equimolar 
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The epidermal water barrier resides in the stratum corneum 
(SC) and is dependent on a highly organized network of 
multi-lamellar membranes comprised of a critical lipid 
composition. The SC membranes are formed from precursor 
membranes packaged in cytoplasmic lamellar bodies in the 
stratum granulosum and delivered to the SC by exocytosis. An 
abnormal lipid composition of the SC membranes often results 
in a disrupted water barrier and the clinical appearance of 
ichthyosis. This cutaneous feature is characteristic of Sjögren-
Larsson syndrome (SLS), an inborn error of lipid metabolism 
caused by deficiency of fatty aldehyde dehydrogenase 
(FALDH). The contribution of FALDH to normal epidermal 
function has become increasingly evident with the recognition 
that this enzyme has an essential role in metabolism of 
several lipids, including fatty aldehydes and alcohols, ether 
glycerolipids, isoprenoid alcohols and certain lipids that 
undergo ω-oxidation, such as leukotriene B4 and very long-
chain fatty acids. in the absence of FALDH, the skin produces 
lamellar bodies that are empty, lack their surrounding vesicle 
membranes or contain granular contents rather then the 
usual cargo membranes. These defective organelles also have 
impaired exocytosis, which results in structurally abnormal, 
deficient multi-lamellar membranes in the SC and a leaky 
water barrier. Although the exact biochemical mechanism 
for the cutaneous pathology is still unclear, studies in SLS 
demonstrate the critical importance of FALDH for normal 
epidermal structure and function.
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ratios of cholesterol, ceramides and free fatty acids, which differs 
from most other membranes. The multi-lamellar SC membranes 
are formed from precursor membranes synthesized in the stratum 
granulosum (SG) and packaged into cytoplasmic lamellar bodies 
(LBs). These LBs deliver their cargo membranes into the SG-SC 
boundary through exocytosis, where they are enzymatically mod-
ified and assembled into mature SC membranes.
The role of the SC membranes and their lipid components 
for the epidermal water barrier has been supported by numerous 
experimental studies indicating that destruction of the SC mem-
branes by topical acetone extraction results in a defective water 
barrier.4 In an effort to replace the SC membranes and restore the 
barrier, these experimental manipulations provoke a coordinated 
biochemical response in the underlying epidermis, with a dramatic 
increase in epidermal lipid synthesis along with proliferation of 
LBs carrying their precursor cargo membranes for delivery to the 
SG-SC interface. This epidermal response to barrier destruction 
mimics, on an accelerated scale, the normal program of epidermal 
differentiation that leads to a functional SC. The importance of 
the lipid composition of the SC membranes is demonstrated by 
the finding that specific enzymatic inhibitors that block synthesis 
of each of the three major lipids, when applied topically to the 
skin, prevent or delay recovery of the barrier.5-7
Inborn errors of lipid metabolism may also affect the SC mem-
branes and cause a chronic barrier defect that is associated with 
the clinical appearance of ichthyosis.8 These rare genetic diseases 
have highlighted some seemingly obscure lipid pathways involving 
phytanic acid, epoxyalcohols, glucosylceramide, triglycerides and 
fatty alcohols, which would otherwise not have been suspected 
to be important for epidermal biology. Additional lipid pathways 
impacting epidermal function will undoubtedly be discovered.
In this review, we illustrate how genetic deficiency of fatty 
aldehyde dehydrogenase (FALDH) has provided insights into the 
role of this enzyme in epidermal structure and function.
Fatty Aldehyde Dehydrogenase Deficiency  
in Sjögren-Larsson Syndrome
Sjögren-Larsson syndrome (SLS) is a rare autosomal reces-
sive disorder of fatty aldehyde and alcohol metabolism that is 92  Dermato-Endocrinology  volume 3 issue 2
longer carboxy-terminal region. FALDHv appears to be targeted 
to the peroxisome, where it probably interacts with a more lim-
ited spectrum of aldehyde substrates.18
FALDH is considered a housekeeping enzyme that is 
expressed in almost all cells and tissues. The enzyme is normally 
present in keratinocytes located throughout the epidermis, 
including basal, spinous and granular layers, but is missing from 
the stratum corneum.19,20
Epidermal Structural Abnormalities Associated  
with FALDH Deficiency in SLS
FALDH deficiency in SLS leads to distinct structural abnor-
malities in the skin. With light microscopy, the patients’ skin 
displays pronounced hyperkeratosis, papillomatosis and acan-
thosis.21 Epidermal hyperplasia is often noted. The granular 
layer is usually normal or mildly thickened, and a slight mono-
nuclear cell infiltration is occasionally seen in the upper dermis. 
In the upper spinous layer, keratinocyte nuclei and nucleoli tend 
to be larger than normal and have more prominent perinuclear 
halos.22 Image analysis of SLS skin sections using Fast Fourier 
Transformation reveals periodicities consistent with increased 
positioning of keratinocyte nuclei in parallel to the basement 
membrane of the epidermis. This may be related to a hyper-
proliferative state in SLS skin as demonstrated by radioactive 
thymidine incorporation.21
At the ultrastructural level, SLS skin exhibits evidence of 
a global disruption of LB formation and secretion.19 The LBs 
in the SG cells are often misshapen, possess granular contents 
rather than their usual cargo membranes, or are empty (Fig. 
1).19,23 Some LBs contain cargo membranes, but have incomplete 
or missing vesicle membranes surrounding them, suggesting 
that structural damage has occurred after their formation. Many 
of the LBs do not undergo exostosis properly and cluster at the 
apical plasma membrane of the SG cells bordering the SC. They 
become entombed in the differentiated corneocytes of the SC, 
where they are seen as discrete cytoplasmic vesicles or lipid inclu-
sions. Membranous lipid inclusions, outside of LBs, can also be 
seen in the cytoplasm of SG cells.24,25 The extracellular mem-
branes in the SC are reduced in number and the membranes 
are often disrupted by foci of non-membranous lipid deposits 
that probably represent lamellar/non-lamellar phase separation 
(Fig. 2).19 The lipid envelope surrounding corneocytes, however, 
appears ultrastructurally intact.
Experimental evidence indicates that the structural abnor-
malities in SLS skin are associated with a defective epidermal 
water barrier. In normal skin, the extensive network of intercel-
lular membranes act to prevent entry of water into the SC, a 
process that is demonstrated by using colloidal lanthanum—an 
electron-dense, water-soluble marker that can be visualized with 
electron microscopy.26 When incubated with colloidal lantha-
num, this tracer is completely excluded from the normal SC. 
In SLS skin, however, colloid lanthanum readily permeates into 
the SC by traversing between corneocytes.19 Lanthanum does 
not diffuse into the corneocytes, indicating that the cells have a 
functionally intact cornified lipid envelope.
characterized by the presence of ichthyosis together with neu-
rologic disease.9,10 The cutaneous symptoms are usually appar-
ent at birth and become more pronounced by several months of 
age. The hyperkeratosis has a generalized distribution but tends 
to spare the face; over time prominent lichenification is often 
seen in the flexures of the arms and legs. The hyperkeratotic, 
scaly skin may vary in appearance from a fine and furfuraceous 
quality to larger more lamellar-like scales, depending on the 
body site. The skin often has an erythematous appearance that 
fades over time. Pruritus is a common complaint of patients. 
The onset of neurologic symptoms consisting of developmental 
delay and mental retardation, spastic diplegia or tetraplegia, sei-
zures and photophobia in the first or second year of life usually 
prompts recognition of SLS rather than another type of ichthy-
otic disorder.
SLS is caused by mutations in ALDH3A2,11,12 which codes for 
FALDH, an enzyme that catalyzes the NAD-dependent oxida-
tion of long-chain aliphatic aldehydes to fatty acids.13 FALDH 
possesses a broad substrate specificity and is capable of oxidizing 
a variety of aliphatic aldehydes ranging from 6- to 24-carbons 
long, including saturated, unsaturated and methyl-branched 
aldehydes.14 The enzyme has a subunit mass of 54 kD and is 
catalytically active as a homodimer.15 Alternative splicing of the 
ALDH3A2 gene results in at least two protein isoforms.16 The 
major isoform is comprised of 485 amino acids and has a car-
boxy-terminal “tail,” which is necessary for its localization to the 
endoplasmic reticulum where it encounters a variety of aldehyde 
substrates.17 A minor protein isoform (FALDHv) is 508 amino 
acids long and differs from the major isoform by possessing a 
Figure 1. Abnormal LBs in the stratum granulosum of SLS skin. (A–C) 
Many organelles appear empty (asterisks) or display non-lamellar 
contents. There is variation in the content and structural appearance of 
cargo membranes. The limiting vesicle membranes of some LBs appear 
disrupted or absent (arrows). reprinted from rizzo et al. Arch Dermatol 
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are often derived from the diet. The most prominent branched-
chain alcohol is phytol, a 20-carbon alcohol produced during 
chlorophyll degradation in the intestine of ruminant animals.38 
It is present at high concentrations in dairy products and green 
leafy vegetables. Phytol is oxidized to phytanic acid in cultured 
skin fibroblasts by FAO, and this reaction is deficient in SLS 
cells.39 Subsequent metabolism of phytanic acid is accomplished 
by the α-oxidation pathway in peroxisomes.40 This pathway gen-
erates pristanal, a 1-carbon-shortened, branched-chain aldehyde 
The Role of FALDH in Lipid Metabolism
Owing to its broad substrate specificity, the role of FALDH in 
lipid metabolism is not restricted to a single substrate or lipid 
pathway. Originally thought to primarily oxidize fatty aldehydes 
derived from straight-chain fatty alcohol metabolism, FALDH is 
now known to occupy a pivotal place in metabolism of a variety 
of aliphatic aldehydes generated by several diverse lipid pathways 
(Fig. 3). Knowledge about the physiologic role of this enzyme 
has been primarily elucidated by studying cells from SLS patients 
who lack FALDH activity.
Fatty alcohol metabolism. Early studies identified FALDH 
as an enzyme necessary for fatty alcohol oxidation.13,27-29 Fatty 
alcohols are synthesized from fatty acids via reduction of their 
acyl-CoA products and used for biosynthesis of wax esters and 
ether glycerolipids in the skin (Fig. 3). Excess fatty alcohols not 
used for biosynthesis are recycled back to fatty acid by action of 
fatty alcohol: NAD oxidoreductase (FAO), a multi-component 
enzyme complex that consists of fatty alcohol dehydrogenase and 
FALDH, which act in a sequential fashion to convert fatty alco-
hol to aldehyde and fatty acid. The pathway for fatty alcohol 
synthesis and oxidation has been named the fatty alcohol cycle, 
in part due to evidence that synthesis and oxidation of fatty 
alcohol occurs simultaneously in cultured skin fibroblasts.30 The 
initial oxidation of fatty alcohol to fatty aldehyde appears rate-
limiting and is followed by a subsequent oxidative step in which 
FALDH catalyzes the oxidation of fatty aldehyde to fatty acid. 
In the absence of FAO activity, SLS cells and tissues accumu-
late long-chain fatty alcohols, primarily hexadecanol (16:0-OH), 
octadecanol (18:0-OH) and octadecenal (18:1-OH).31-33 Shorter 
and longer alcohols are also oxidized by FAO, but other isozymes 
in SLS cells apparently provide enzyme redundancy to prevent 
their accumulation.
Fatty alcohols are precursors for the synthesis of wax esters and 
ether glycerolipids, two pathways that are particularly active in 
skin (Fig. 3). Although wax esters34 
and ether glycerolipids35 are thought 
to be surface lipids that are generated 
in sebaceous glands, recent studies 
have demonstrated that both lipids 
can also be synthesized in cultured 
keratinocytes.36,37 Fatty alcohols are 
present in low concentrations in 
normal cultured keratinocytes, but 
SLS keratinocytes, which have defi-
cient FAO activity, accumulate up 
to 25-fold more fatty alcohol than 
normal.36 Studies using radioactive 
octadecanol demonstrate that the 
excess fatty alcohol in SLS keratino-
cytes is diverted into synthesis of wax 
esters and neutral ether glycerolipids, 
resulting in large increases in the cel-
lular content of these lipids.
In contrast to straight-chain alco-
hols, branched-chain fatty alcohols 
Figure 2. Abnormal SC membranes in SLS skin. Note the paucity of 
membrane bilayers in some regions (arrows) and lamellar domains that 
are interspersed with lacunae filled with non-lamellar lipid material 
(asterisks). Entombed lamellar contents in can be seen in corneocyte 
cytosol (open arrows). ruthenium tetroxide post-fixation. reprinted 
from rizzo et al. Arch Dermatol res 2010; 302:443.
Figure 3. The role of FALDH in lipid metabolism. Lipid substrates that are inferred to require FALDH for 
metabolism, but lack experimental confirmation, are indicated with a question mark.94  Dermato-Endocrinology  volume 3 issue 2
be metabolized to generate sphingosine-1-phosphate (S1P), a 
potent lipid cell-signaling molecule with effects on cell prolif-
eration, calcium homeostasis, cell migration and immune func-
tion.53 The degradation of S1P is catalyzed by S1P lyase, an 
irreversible reaction that yields hexadecenal. This fatty aldehyde 
is subsequently oxidized to fatty acid by a yet unidentified alde-
hyde dehydrogenase, possibly FALDH.
Oxidative stress generates several toxic aldehydes, including 
4-hydroxynonenal (4-HNE), by peroxidative cleavage of poly-
unsaturated fatty acids.54 4-HNE is among the most reactive 
aldehydes and is detoxified via three mechanisms: oxidation to 
fatty acid, reduction to fatty alcohol and conjugation with glu-
tathione.55 Several aldehyde dehydrogenase isozymes catalyze 
the oxidation of 4-HNE, including ALDH3A1, which is closely 
related to FALDH.56,57 Recent studies indicate that overexpres-
sion of FALDH protects cultured cells from the cytotoxic effects 
of 4-HNE, suggesting that FALDH may play a physiologic role 
in protection of cells from oxidative stress.58,59 The quantitative 
contribution of FALDH to this process, however, is unclear and 
may vary among tissues.
With oxidative stress, reactive oxygen species also attack the 
vinyl ether bond of plasmalogen lipids to release the alkyl chain 
as fatty aldehyde.60 It is likely, but not proven, that FALDH 
catalyzes the oxidation of these long-chain aldehydes to fatty 
acids.
Chlorinated fatty aldehydes (i.e., 2-chloro-hexadecanal) are 
produced by activated phagocytes as a product of lipid peroxida-
tion.61 Metabolism of 2-chloro-hexadecanal to 2-chloro-hexadec-
anoic acid has been demonstrated in human endothelial cells,62 
and mutant FALDH-deficient Chinese hamster cells have been 
found to be deficient in this oxidative step.63 It is not known, 
however, to what extent chlorinated fatty aldehydes are generated 
in the epidermis.
Fatty acid ω-oxidation. ω-Oxidation is a pathway for fatty 
acid degradation in which the ω-terminal end of the aliphatic 
chain is enzymatically hydroxylated and subsequently oxidized 
to a carboxyl-group forming a dicarboxylic acid. This alcohol-
to-acid conversion proceeds through an aldehyde intermedi-
ate (ω-oxo fatty acid) and is analogous to that seen in primary 
fatty alcohol oxidation (Fig. 3). Evidence is emerging that FAO/
FALDH is necessary for ω-oxidation of certain fatty acids, 
including select eicosanoids. Metabolism of leukotriene B4,   
a potent eicosanoid inflammatory mediator derived from ara-
chidonic acid, proceeds via P450-mediated hydroxylation of the 
ω-terminal end of the fatty acid, followed by conversion to a 
dicarboxylic acid and subsequent degradation in peroxisomes.64 
The oxidation of 20-hydroxy-leukotriene B4 to 20-carboxy-
leukotriene B4 is catalyzed by FAO/FALDH. This metabolic 
step is profoundly deficient in SLS patients, and results in tis-
sue accumulation and urinary excretion of leukotriene B4 
and 20-hydroxy-leukotriene B4.65 Other eicosanoid lipids also 
undergo ω-oxidation as the major route of degradation, includ-
ing the epoxyalcohols66 and certain prostaglandins,67 although 
FAO/FALDH has not yet been demonstrated to be necessary 
for their metabolism. In a similar fashion, very long-chain fatty 
acids can also be ω-oxidized to dicarboxylic acids via a FAO/
that is oxidized to pristanic acid. Pristanal is a substrate for 
FALDH41 and its oxidation to pristanic acid is probably medi-
ated by FALDHv located in peroxisomes.18,42 Thus, FALDH is 
implicated in two steps in phytol/phytanic acid metabolism. 
Nevertheless, neither phytol nor phytanic acid have been shown 
to accumulate in plasma from SLS patients,41 suggesting that 
alternate enzymes may exist to carry out these reactions in some 
tissues.
Preliminary studies indicate that other branched-chain alco-
hols are also oxidized by FAO, including isoprenoid alcohols that 
are products of the mevalonate pathway.43 Mevalonic acid is a 
product of hydroxymethylglutaryl-CoA (HMG-CoA) reductase 
and used to synthesize 5-carbon isoprenoid units that are linked 
together to generate farnesyl-PP, a key substrate precursor for 
biosynthesis of cholesterol, dolichols and coenzyme Q. The con-
version of farnesyl-PP to geranylgeranyl-PP is a committed step 
toward cholesterol synthesis. Both farnesyl-PP and geranylgera-
nyl-PP can be dephosphorylated to farnesol and geranylgeraniol, 
respectively, and subsequently oxidized to their fatty acids.44,45 
This oxidative reaction is impaired in SLS fibroblasts, which 
implicates FAO/FALDH in this metabolic step.43
Fatty aldehyde metabolism. Distinct from its role in fatty 
alcohol metabolism, FALDH is involved in oxidation of fatty 
aldehydes originating from catabolism of several additional lip-
ids, including ether glycerolipids, and certain fatty acids and 
eicosanoids that undergo ω-oxidation (Fig. 3).
Ether glycerolipids are a source of fatty aldehydes generated 
through normal catabolism,46 and by non-enzymatic peroxida-
tion (see below). Ether glycerolipids in mammals are character-
ized by the presence of a long-chain alkyl group attached to the 
sn-1 carbon of glycerol via an ether bond.47 The alkyl moiety is 
derived from fatty alcohols that are chiefly 16- to 18-carbons 
long (Fig. 3).46 Ether glycerolipids include plasmalogen forms of 
phospholipids (phosphatidyl-choline, -ethanolamine and -ser-
ine) in which the sn-1 position is occupied by a 1-O-alkenyl 
chain with an unsaturated vinyl ether bond. Plasmalogens are 
present at high concentrations in certain cells (erythrocytes) 
and tissues (heart, brain, tumors), but not in skin. Instead, 
neutral ether glycerolipids, such as 1-O-alkyl-2,3-diacyglycerol, 
are synthesized by sebaceous glands and secreted onto the sur-
face of the skin as a component of sebum.35 1-O-Alkyl-2,3-
diacyglycerol is also synthesized in cultured keratinocytes,36,37 
but it is not normally present in SC membranes. The catabo-
lism of ether glycerolipids involves enzymatic cleavage of the 
1-O-alkyl bond, which releases the alkyl group as fatty aldehyde 
(Fig. 3).48 Studies on the metabolism of 1-O-alkylglycerol indi-
cate that the fatty aldehyde is normally oxidized to fatty acid 
by FALDH and this reaction is impaired in SLS fibroblasts and 
SLS keratinocytes.49
Ceramides comprise one of the three major classes of lipids in 
the SC membranes. The ceramides are structurally complex and 
some molecular species, such as acylceramides, are unique to the 
skin.50 In contrast to its extracellular structural role in SC mem-
branes, intracellular ceramide and its metabolites have a central 
role in regulating cellular responses to various forms of stress,51 
including UV-induced keratinocyte apoptosis.52 Ceramides can www.landesbioscience.com Dermato-Endocrinology  95
Long-chain alcohols have a high partition coefficient for biological 
membranes and intercalate into cellular membranes rather than 
exist free in solution.69,70 Hexadecanol has been reported to inhibit 
lipase activity in vitro,71 and could potentially cause secondary tri-
glyceride accumulation in the epidermis or prevent production of 
free fatty acids. On the other hand, feeding studies in rodents have 
revealed no harmful effects of octadecanol, even at high dietary 
intake. Moreover, topical lotions containing long-chain alcohols 
do not induce skin abnormalities in normal humans. It is unclear, 
however, to what extent these lotion-derived alcohols penetrate 
the SC and accumulate in the lower layers of the skin.
Cultured skin keratinocytes from SLS patients accumulate 
large amounts of free fatty alcohols, wax esters and 1-O-alkyl-
2,3-diacylglycerol, and it is a reasonable expectation that similar 
biochemical changes occur in vivo. Wax esters34 and 1-O-alkyl-
2,3-diacylglycerol35 are usually present on the surface of the skin, 
but their abnormal accumulation in cultured SLS keratinocytes 
suggests a potential role in the pathogenesis of defective LB 
membranes.
Aside from a direct physical effect on keratinocyte mem-
branes, lipid accumulation in SLS may be detrimental by inter-
fering with normal cell signaling pathways in the skin. Epidermal 
differentiation is induced by certain physiologic agents, includ-
ing increased intracellular calcium,72 cholesterol sulfate73,74 and 
1,25-dihydroxyvitamin D3,75 that act directly or indirectly to 
increase 1,2-diacylglycerol and thereby stimulate protein kinase 
C (PKC) activity.76 Neutral ether glycerolipids can also modulate 
PKC activity. For example, 1-O-alkylglycerol has been shown to 
inhibit PKC in rat brain,77,78 whereas 1-O-alkyl-2-acylglycerol has 
the opposite effect.79 1-O-alkyl-2,3-diacylglycerol accumulates in 
cultured SLS keratinocytes, but its effect on keratinocyte PKC 
activity is not known. Furthermore, medium-chain fatty alco-
hols (C8-10) either enhance or inhibit PKC activity in a complex 
manner.80 The effects of longer chain alcohols on PKC activity 
have not been reported.
FALDH-dependent reaction,68 but this represents a minor route 
for its degradation. In light of these studies, it is possible that 
FAO/FALDH is involved in metabolism of additional fatty acids 
that undergo ω-oxidation.
Biochemical Pathogenesis  
of Epidermal Dysfunction in SLS
The biochemical mechanisms responsible for epidermal dysfunc-
tion in SLS are undoubtedly complex. In SLS patients, FALDH 
activity is deficient in all epidermal cells. Nevertheless, histologic 
studies of SLS skin point to the SG as the most relevant site of 
pathogenesis, and abnormalities in LB structure and secretion as 
the primary target with defective SC membrane arrays as a con-
sequential effect.
Which biochemical abnormalities in SLS might be responsible 
for the defective LB structure and secretion? Owing to the role 
of FALDH in several fatty alcohol/aldehyde pathways (Table 1) 
and very limited biochemical studies of SLS skin, any discussion 
of pathogenic mechanisms will necessarily appear speculative. It 
is, however, unlikely that perturbations in all potential lipid path-
ways contribute equally to the epidermal dysfunction. In most 
lipid pathways, FALDH acts in a catabolic role to degrade its 
alcohol/aldehyde substrate, which suggests that accumulation of a 
toxic lipid is more likely to be pathogenic to the skin than failure 
to produce a key lipid product. Nevertheless, the epidermal patho-
genesis may arise from one or more lipid abnormalities, including 
(1) accumulation of fatty alcohol or its metabolic products, (2) 
toxic effects of fatty aldehydes, (3) defective isoprenol oxidation, 
(4) impaired fatty acid ω-oxidation or (5) altered fatty acid and 
ceramide metabolism.
Accumulation of fatty alcohol or its metabolic products. 
The epidermal consequences of fatty alcohol accumulation are 
poorly understood. Fatty alcohols that accumulate in SLS seem 
to be restricted to those that are 16- to 18-carbons long.31,33,36 
Table 1. Lipid pathways affected by FALDH deficiency in SLS patients or FALDH-deficient cells
Lipid pathway Aldehyde precursor lipid FALDH substrate Abnormality demonstrated in SLS
Fatty alcohol oxidation Straight-chain alcohols
Hexadecanal, octadecanal, 
 octadecenal
Yes (fibroblasts, keratinocytes, 
plasma)
Branched-chain alcohols (Phytol) Phytenal Yes (fibroblasts)
isoprenoid alcohols (Farnesol, 
Geranylgeraniol)
Farnesal, Geranylgeranal Yes (fibroblasts)
Ether glycerolipid 
catabolism
Ether glycerolipids Hexadecanal, octadecanal Yes (fibroblasts, keratinocytes)
Fatty acid ω-oxidation Leukotriene B4 → 20-OH-leukotriene B4 20-Oxo-leukotriene B4 Yes (fibroblasts, urine)
very long-chain fatty acids ω-Oxo-very long-chain fatty acid Yes (fibroblasts)
Epoxyalcohols 12R-HXA3 → 12R-TXA3 20-OH-TXA3 and 20-oxo-TXA3 Not determined




Ether glycerolipids (plasmalogens) Hexadecanal, Octadecanal Not determined
Ether glycerolipids (plasmalogens) 2-Chloro-hexadecanal
Not determined (demonstrated in 
FALDH-deficient hamster cells)
Ceramide catabolism Sphingosine-1-phosphate Hexadecenal Not determined96  Dermato-Endocrinology  volume 3 issue 2
that cause ichthyosis have been identified in two enzymes, 
12R-lipoxygenase and hepoxilin synthase, that sequentially 
act to synthesize the epoxyalcohol commonly known as 
(R)-hepoxilin-A3 (abbreviated HXA3).93,94 Subsequent metab-
olism of HXA3 forms (R)-trioxilin-A3 (abbreviated TXA3) 
that, in turn, is metabolized by ω-oxidation.66 TXA3 is ini-
tially ω-hydroxylated to 20-hydroxy-TXA3 and subsequently 
oxidized to 20-carboxy-TXA3, analogous to the ω-oxidation 
of leukotriene B4 that is deficient in SLS. Since genetic 
defects in synthesis of HXA3 cause ichthyosis, it follows that 
HXA3 or one of its metabolites is necessary for normal epi-
dermal development. In fact, TXA3 has been found to be a 
ligand for PPARα95 and may act, like farnesol, in stimulat-
ing epidermal gene transcription. If FAO were necessary for 
20-hydroxy-TXA3 oxidation, accumulation of TXA3 and its 
ω-hydroxylated metabolite is expected to induce overexpres-
sion of PPARα-sensitive genes, which might disrupt lipid 
metabolism in keratinocytes. Alternately, if 20-carboxy-TXA3 
(or its downstream metabolite) is the key lipid in this pathway 
required for normal epidermal differentiation, its decreased 
production in SLS may lead to ichthyosis, similar to the other 
genetic defects in the HXA3 pathway. The inference that the 
ichthyosis arises from defective epoxyalcohol metabolism, 
however, begs experimental support, since other enzymes can 
catalyze the oxidation of 20-hydroxy-eicosanoids.96
Although not involved in keratinocyte differentiation, accu-
mulation of leukotriene B4 and/or 20-hydroxy-leukotriene B4 in 
SLS due to FAO/FALDH deficiency is likely responsible for the 
pruritus seen in SLS patients.97 This conclusion is supported by 
experimental studies in mice showing that the intradermal injec-
tion of leukotriene B4 causes itching.98 In SLS patients, thera-
peutic reductions in leukotriene B4 levels can be achieved by 
pharmacologically blocking its synthesis, which leads to clinical 
improvement in the pruritus of some patients.99
Altered fatty acid and ceramide metabolism. The free fatty 
acids in the SC membranes largely originate from hydrolysis of 
phospholipids during epidermal differentiation.100 It is unlikely 
that the oxidation of alcohol/aldehyde lipids by FAO/FALDH 
produces a substantial amount of fatty acids for synthesis of SC 
membranes, although the relative contribution of this enzyme to 
the epidermal fatty acid pool has not been measured.
There is evidence, however, for indirect effects of FALDH defi-
ciency on fatty acid metabolism. Certain polyunsaturated fatty 
acids that arise from δ-6 desaturation of linoleic acid (C18:2) are 
reduced in SLS serum.101 Linoleic acid itself is an essential fatty 
acid that is incorporated into acylceramide (ceramide-1).50 This 
ceramide is important for epidermal barrier function as under-
scored by a reduced ceramide-1 content and cutaneous desqua-
mation seen in essential fatty acid deficiency.102 However, linoleic 
acid levels are normal in SLS serum.101 Moreover, SLS fibroblasts 
have normal δ-6 desaturase activity104 and cultured SLS kerati-
nocytes exhibit no abnormalities in polyunsaturated fatty acids,36 
suggesting that the serum fatty acid abnormalities are secondary 
alterations.
Scales from SLS patients have mildly reduced levels of 
ceramide-1 and ceramide-6,103 but a direct metabolic connection 
Unlike straight chain fatty alcohols, mice fed large amounts 
of phytol develop cutaneous and neurologic symptoms after 
several days, but these symptoms may be mediated solely or in 
part by increases in phytanic acid.81 Patients with Refsum dis-
ease, who are genetically deficient in α-oxidation and store large 
amounts of phytanic acid in tissues, exhibit ichthyosis.8 Defective 
oxidation of phytol to phytanic acid occurs in SLS fibroblasts,39 
but neither phytanic acid41 or phytol (Rizzo WB, unpublished 
data) is elevated in plasma from SLS patients. Furthermore, it is 
unlikely that phytol/phytanic acid metabolism is responsible for 
the ichthyosis in SLS, since cutaneous disease is already present 
at birth before these dietary lipids are consumed.
Toxic effects of fatty aldehydes. Fatty aldehydes are poten-
tially toxic molecules because of their propensity to form cova-
lent adducts with lipids and proteins.54 Long-chain aldehydes 
that cannot be metabolized by FALDH can form Schiff base 
adducts with phosphatidylethanolamine (PE), resulting in accu-
mulation of N-alkyl-PE.41,82,83 Formation of N-alky-PE replaces 
the positively charged amino group of the ethanolamine moiety 
of PE with an uncharged hydrophobic alkyl side chain. If suffi-
cient amounts of N-alkyl-PE were to accumulate, LB membrane 
assembly or stability could be affected. Aldehyde adducts with 
other lipids containing free amino groups could also contribute 
to the epidermal pathology in SLS.
In addition to lipid adducts, formation of aldehyde adducts 
with ε-amino groups of lysine residues in epidermal proteins 
could have a more widespread effect on epidermal function. To 
date, however, aldehyde-protein adducts have not been investi-
gated in SLS.
Defective isoprenol oxidation. Defective farnesol oxida-
tion in SLS may have several biologically important effects on 
the skin. Farnesol induces differentiation of cultured human 
keratinocytes via a peroxisome proliferator activated receptor-α 
(PPARα) dependent mechanism and stimulates transcription of 
epidermal-specific genes.84 However, activation of PPARα and 
related PPAR isoforms (PPARβ/δ and PPARγ) tend to stimulate 
lipid synthesis genes in the epidermis and enhance formation of 
the permeability barrier.85 It is possible, however, that dysregula-
tion of PPAR-sensitive gene expression by farnesol could occur in 
the skin and contribute to the pathogenesis of SLS.
Farnesol also has the ability to decrease cholesterol synthe-
sis by promoting the degradation of HMG-CoA reductase86 
and inhibiting mevalonate kinase.87 In rodents, topical applica-
tion of lovastatin, which inhibits HMG-CoA reductase, results 
in abnormal LB formation, a leaky epidermal water barrier and 
an ichthyotic appearance.88,89 Although the mechanism for this 
cutaneous response may be more complex than simply reduc-
tion in cholesterol synthesis, farnesol accumulation in SLS skin 
may mimic the effects of lovastatin on HMG-CoA reductase and 
cause a similar cutaneous phenotype.
Defective fatty acid ω-oxidation. It has been speculated 
that the ichthyosis in SLS arises from defective metabo-
lism of 12R-epoxyalcohol lipids (hepoxilins) that are derived 
from arachidonic acid.90 Hepoxilins exist as R- or S-isomers, 
and have potent biological activities that are mediated via an 
intracellular G-coupled protein receptor.91,92 Genetic defects www.landesbioscience.com Dermato-Endocrinology  97
primarily responsible for the cutaneous disease and it is possible 
that multiple lipid abnormalities are involved. For understand-
ing the epidermal pathogenesis, it will be critically important to   
better define the lipid composition of the skin of SLS patients 
and to develop an animal model for investigation. The poten-
tial contribution of the lipid abnormalities to signaling pathways 
and epidermal gene expression are intriguing possibilities that 
remain to be explored. Nevertheless, elucidation of the biochemi-
cal mechanisms resulting in abnormal epidermal structure and 
function should lead to the development of rational, targeted 
therapeutic approaches for the cutaneous symptoms of SLS.
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between FALDH deficiency and ceramide synthesis in skin is 
not known. Nor is it known whether the fatty aldehyde pro-
duced from ceramide degradation influences S1P or intracel-
lular ceramide levels in keratinocytes. The reduced ceramide 
content in scales of SLS patients may nevertheless contribute to 
the water barrier defect, especially in combination with other 
lipid changes.
Conclusion
In summary, the available evidence suggests that the cutaneous 
pathogenesis of SLS originates from one or more lipid abnormali-
ties that disrupts the formation and secretion of LBs, and leads to 
defective SC membranes and a leaky water barrier. It is likely that 
the skin responds by a process of reactive hyperproliferation in 
an attempt to restore the water barrier by making more defective 
SC, which results in hyperkeratosis and overt ichthyosis. FALDH 
deficiency causes several potentially deleterious lipid abnormali-
ties. To date, however, no single lipid pathway has emerged as 
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